Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer

Bone Marrow Transplantation volume 26, pages 729–735 (2000)Cite this article

Abstract

Between April 1997 and March 1998 we evaluated the immune response and outcome in 11 chemosensitive patients who were treated with the anti-idiotype antibody vaccine TriAb after recovery from intensive therapy and autologous stem cell transplant (ASCT). Triab was commenced after recovery from the acute effects of ASCT; a minimum interval of 1 month was required from completion of consolidation radiotherapy, if given. Nine patients (82%) manifest anti-anti-idiotype antibody (Ab3) responses post ASCT. The maximal Ab3 response was seen after a median of 10 doses (range 5–20), which corresponded to a median of 14 months (range 5–19) post ASCT. Evidence of a T cell proliferative response was seen in eight patients; the response was modest in most of these. At a median follow-up of 24 months (range 22–33) after ASCT, four patients are alive without evidence of disease progression. All four of these patients were in the subgroup with more vigorous immune responses. Subsequent efforts have been directed toward the achievement of higher levels of immune responses more rapidly post ASCT. Bone Marrow Transplantation (2000) 26, 729–735.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Antman KH, Rowlings PA, Vaughn WD et al. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America J Clin Oncol 1997 15: 1870–1879

    Article  CAS  PubMed  Google Scholar 

  2. Ayash LJ, Elias A, Schwartz G et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin J Clin Oncol 1996 14: 2984–2992

    Article  CAS  PubMed  Google Scholar 

  3. Kennedy MJ, Vogelsang GB, Beveridge RA et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer J Clin Oncol 1993 11: 478–484

    Article  CAS  PubMed  Google Scholar 

  4. Knutson KL, Schiffman K, Rinn K, Disis ML . Immunotherapeutic approaches for the treatment of breast cancer J Mammary Gland Biol Neoplasia 1999 4: 353–365

    Article  CAS  PubMed  Google Scholar 

  5. Hadden JW . The immunology and immunotherapy of breast cancer: an update Int J Immunopharm 1999 21: 79–101

    Article  CAS  Google Scholar 

  6. Goydos JS, Elder E, Whiteside TL et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma J Surg Res 1996 63: 298–304

    Article  CAS  PubMed  Google Scholar 

  7. Karanikas V, Hwang LA, Pearson J et al. Antibody and T-cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein J Clin Invest 1997 100: 2783–2792

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Brossart P, Heinrich KS, Stuhler G et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC-1 tumor antigen for broadly applicable vaccine therapies Blood 1999 93: 4309–4317

    Article  CAS  PubMed  Google Scholar 

  9. Gilweski T, Dickler M . Adluri R et al. Vaccination of high-risk breast cancer patients (PTS) with MUC-1 (32aa) keyhole limpet hemocyanin (KLH) conjugate plus QS-21: preliminary results Proc Am Soc Clin Oncol 1998 17: 433 (Abstr. 1670)

    Google Scholar 

  10. Von Mehren M, Davey M, Rivera V et al. Phase I trial with ALVAC-CEA B7.1. In immunization in advanced CEA-expressing adenocarcinomas Proc Am Soc Oncol 1999 18: 437 (Abstr. 1686)

    Google Scholar 

  11. Longnecker BM, Reddish M, Koganty R, MacLeon GD . Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant Ann NY Acad Sci 1993 690: 276–296

    Article  Google Scholar 

  12. Lindenmann J . Speculations on idiotypes and homobodies Ann Immunol (Paris) 1973 124: 171–184

    CAS  Google Scholar 

  13. Jerne NK . Towards a network theory of the immune system Ann Immunol (Paris) 1974 125C: 373–389

    CAS  Google Scholar 

  14. Stevenson FK, Gordon J . Immunization of idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation J Immunol 1983 13: 970–973

    Google Scholar 

  15. Sugai S, Palmer DW, Talal N, Witz IP . Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice J Exp Med 1974 140: 1547–1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ruiz PJ, Wolkowicz R, Waisman A et al. Idiotypic immunization induced immunity to mutant p53 and tumor rejection induced by idiotypic immunization Nature Med 1998 4: 710–712

    Article  CAS  PubMed  Google Scholar 

  17. Raychaudhuri S, Saeki Y, Fuji H, Kohler H . Tumor-specific idiotype vaccines, IV. Analysis of the idiotypic network in tumor immunity J Immunol 1987 139: 3902–3910

    CAS  PubMed  Google Scholar 

  18. Raychaudhuri S, Saeki Y, Chen JJ, Kohler H . Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen J Immunol 1986 137: 1743–1749

    CAS  PubMed  Google Scholar 

  19. Raychaudhuri S, Saeki Y, Chen JJ et al. Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta) J Immunol 1987 139: 271–278

    CAS  PubMed  Google Scholar 

  20. Raychaudhuri S, Saeki Y, Chen JJ et al. Tumor specific idiotype vaccines. III. Induction of T helper cells by anti-idiotype and tumor cells J Immunol 1987 139: 2096–2102

    CAS  PubMed  Google Scholar 

  21. Kennedy RC, Dreesman GR, Butel JS, Lanford RE . Suppression of in vivo tumor formation induced by simian virus 40 transformed cells in mice receiving anti-idiotypic antibodies J Exp Med 1985 161: 1432–1439

    Article  CAS  PubMed  Google Scholar 

  22. Nelson KA, George E, Swenson C et al. Immunotherapy of murine sarcomas with auto- anti-idiotypic monoclonal antibodies which bind to tumor-specific T-cells J Immunol 1987 139: 2110–2117

    CAS  PubMed  Google Scholar 

  23. Foon KA, Chakraborty M, John WJ et al. Immune response to carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine J Clin Invest 1995 96: 334–342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen Clin Cancer Res 1997 3: 1267–1276

    CAS  PubMed  Google Scholar 

  25. Mittelman A, Chen ZJ, Yank H et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK 2–23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proc Natl Acad Sci USA 1992 89: 466–470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Foon KA, Lutzky J . Baral N et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialo- ganglioside GD2 J Clin Oncol 2000 18: 376–384

    Article  CAS  PubMed  Google Scholar 

  27. Kwak LW, Campbell MJ, Cerwinski D et al. Induction of immune response in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors New Engl J Med 1992 327: 1209–1238

    Article  CAS  PubMed  Google Scholar 

  28. Foon KA, Oseroff AR, Viackus L et al. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restrictive T-cell antigen Clin Cancer Res 1995 1: 1285–1294

    CAS  PubMed  Google Scholar 

  29. Ceriani RL, Peterson JA, Lee JY et al. Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule Somatic Cell Genetics 1983 9: 415–427

    Article  CAS  PubMed  Google Scholar 

  30. Ceriani RL, Blank EW, Peterson JA et al. Immunotherapeutic preclinical evaluation of anti-human milk fat globule MoAbs Mc5 and BrE-1 Antibody Immunoconj Radiopharma 1990 3: 181–198

    Google Scholar 

  31. Edwards DP, Grzyb KT, Dressler LG et al. Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer Cancer Res 1986 46: 1306–1317

    CAS  PubMed  Google Scholar 

  32. Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S et al. Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. In: Ceriani R (ed) Proceedings of the 5th International Workshop on Breast Cancer Therapy and Immunology Plenum: New York 1994 387–401

    Google Scholar 

  33. TriAb™ Investigator’s Brochure Titan Pharmaceuticals, Inc South San Francisco, CA May 20 1998

  34. Munn RK, Hutchins L, Garrison J et al. Immune responses in patients with breast cancer treated with an anti-idiotype antibody that mimics the human milk fat globule (HMFG) antigen Proc Am Soc Clin Oncol 1998 17: 428 (Abstr. 1648)

    Google Scholar 

  35. Stemmer SM, Cagnoni PJ, Sphall EJ et al. High dose paclitaxel, cyclophosphamide and cisplatin with autologous progenitor support: a phase I trial J Clin Oncol 1996 14: 1463–1472

    Article  CAS  PubMed  Google Scholar 

  36. Reece D, Glenn C, Hale G et al. Acute effects of multiple doses of ethyol® (amifostine) [AF] plus high-dose paclitaxel (P), cyclophosphamide (CY), cisplatin (cDDP) and autologous stem cell transplantation (ASCT) in patients (PTS) with metastatic breast cancer Proc Am Soc Clin Oncol 1998 17: 94 (Abstr. 364)

    Google Scholar 

  37. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 1992 10: 102–110

    Article  CAS  PubMed  Google Scholar 

  38. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen J Clin Oncol 1999 17: 2889–2895

    Article  CAS  PubMed  Google Scholar 

  39. Chatterjee SK, Tripathi PK, Chakraborty M et al. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of anti-idiotype antibody Cancer Res 1998 58: 1217–1224

    CAS  PubMed  Google Scholar 

  40. Guillaume T, Rubinstein D, Symann M . Immune reconstitution and immunotherapy after autologous stem cell transplantation Blood 1998 92: 1471–1490

    Article  CAS  PubMed  Google Scholar 

  41. Rutella S, Rumi C, Laurenti L et al. Immune constitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants Br J Haematol 2000 108: 105–115

    Article  CAS  PubMed  Google Scholar 

  42. Dreger P, Viehmann K, von Neuhoff N et al. Autografting of highly purified peripheral blood progenitor cells following myeloblative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery Bone Marrow Transplant 1999 24: 153–161

    Article  CAS  PubMed  Google Scholar 

  43. Holmberg LA, Boeckh M, Hooper H et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation Blood 1999 94: 4029–4035

    Article  CAS  PubMed  Google Scholar 

  44. Rowlings PA, Williams SF, Antman KH et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer JAMA 1999 282: 1335–1343

    Article  CAS  PubMed  Google Scholar 

  45. Sandmaier BM, Oparin DV, Holmberg LA et al. Evidence of a cellular immune response against Sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope-STn-KLH cancer vaccine J Immunother 1999 22: 54–66

    Article  CAS  PubMed  Google Scholar 

  46. Bhattachary-Chatterjee M, Baral RN, Chatterjee SK et al. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine Cancer Immunol Immunother (in press)

  47. Avanzini MA, Carra AM, Maccario R et al. Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls J Clin Immunol 1998 18: 193–201

    Article  CAS  PubMed  Google Scholar 

  48. Adluri S, Gilewski T, Zhang S et al. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21 Br J Cancer 1999 79: 1806–1812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Reece D, Foon K, Chatterjee M et al. Anti-idiotype antibody vaccination in conjunction with intensive therapy (IT) and autologous stem cell transplantation (ASCT) for patients (PTS) with metastatic breast cancer Proc Am Soc Clin Oncol 1999 18: 124 (Abstr. 473)

    Google Scholar 

Download references

Acknowledgements

We would like to thank Trudy Winkle and Brenda Bailey for assistance in the preparation of this manuscript, as well as Vanessa Bard for help with data collection.

Author information

Authors and Affiliations

  1. University of Kentucky Blood and Marrow Transplant Program, Lexington, KY, USA

    DE Reece, GA Hale, DS Howard, RK Munn, R Nath, BA Plummer & GL Phillips

  2. University of Cincinnati, Barrett Cancer Center, Cincinnati, OH, USA

    KA Foon & M Bhattacharya-Chatterjee

  3. Titan Pharmaceuticals, Inc., South San Francisco, CA, USA

    A Teitelbaum

Authors
  1. DE Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. KA Foon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Bhattacharya-Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. GA Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. DS Howard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. RK Munn
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Nath
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. BA Plummer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Teitelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. GL Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reece, D., Foon, K., Bhattacharya-Chatterjee, M. et al. Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transplant 26, 729–735 (2000). https://doi.org/10.1038/sj.bmt.1702607

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702607

Keywords

This article is cited by

Search

Advanced search

Quick links